Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 1,001–1,056 of 1,056
Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ
Bartkova, J., Barnes, D. M., Millis, R. R., & Gullick, W. J. (1990) · Human Pathology · doi:10.1016/0046-8177(90)90154-w · Cited by 159
Costa, R. L. B., & Czerniecki, B. J. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0153-3 · Cited by 158
Scott, G. K., Robles, R., Park, J. W., Montgomery, P. A., Daniel, J., Holmes, W. E., Lee, J., Keller, G. A., Li, W. L., & Fendly, B. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.4.2247 · Cited by 158
“mammary origin, in which the overexpressed receptor contributes to aggressive tumor growth and reduced patient survival (13, 37).”
BackgroundJhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
“One of the genes on the panel was the ERBB2 (HER2) gene that encodes a member of the ERBB family of receptor tyrosine kinases and is a key proto-oncogene in solid tumors [1, 2].”
BackgroundKlempner, S. J., Myers, A. P., & Cantley, L. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0063 · Cited by 148
Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3407 · Cited by 151
“Overexpression/amplification of HER2 occurs in approximately 20% of human breast cancers and is associated with a more aggressive phenotype and worse prognosis (8-9).”
BackgroundMuller, W. J., Arteaga, C. L., Muthuswamy, S. K., Siegel, P. M., Webster, M. A., Cardiff, R. D., Meise, K. S., Li, F., Halter, S. A., & Coffey, R. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5726 · Cited by 147
“For example, amplification and consequent overexpression of neu have been observed in a significant proportion of human breast cancers and appear to be inversely correlated with patient survival (9, 12, 25, 32 , 33, 37).”
BackgroundLiang, K., Esteva, F. J., Albarracin, C., Stemke-Hale, K., Lu, Y., Bianchini, G., Yang, C.-Y., Li, Y., Li, X., Chen, C.-T., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.025 · Cited by 139
“These downstream signaling pathways activated by EPO via EpoR overlap substantially or interact with those activated by human epidermal growth factor receptor-2 (HER2), a member of the HER family, which is overexpressed in approximately 25% of breast cancers (Slamon et al., 1987).”
Monoclonal antibody-based molecular imaging strategies and theranostic opportunities
Dammes, N., & Peer, D. (2020) · Theranostics · doi:10.7150/thno.37443 · Cited by 138
“Human epidermal growth factor 2 (HER2) was identified in the 1980s as an oncogene in breast cancer [95] and since then, it has been a focal point of research in the past decades.”
BackgroundMcKillop, D., Hutchison, M., Partridge, E. A., Bushby, N., Cooper, C. M. F., Clarkson-Jones, J. A., Herron, W., & Swaisland, H. C. (2004) · Xenobiotica · doi:10.1080/00498250400009171 · Cited by 130
“…as well as erbB2, could lead to cellular transformation and was linked to poor prognosis in cancer (Sainsbury et al. 1985, Di Fiore et al. 1987, Slamon et al. 1987), these erb receptors have been viewed as an attractive target for novel antitumour therapies and there are now a number of agents…”
BackgroundChakrabarty, A., Bhola, N. E., Sutton, C., Ghosh, R., Kuba, M. G., Dave, B., Chang, J. C., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2440 · Cited by 130
“org Cancer Res; 73(3) February 1, 2013 1195”
InfluentialMinuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O’Brien, T., Mendoza, A. D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.335 · Cited by 127
“Approximately 20–25% of breast cancers are characterised by HER2 protein overexpression or gene amplification, and such events are associated with poor prognosis (Slamon et al, 1987).”
BackgroundFinkle, D., Quan, Z. R., Asghari, V., Kloss, J., Ghaboosi, N., Mai, E., Wong, W. L., Hollingshead, P., Schwall, R., Koeppen, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0448 · Cited by 125
Cao, Z., Wu, X., Yen, L., Sweeney, C., & Carraway, K. L. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01245-06 · Cited by 119
“For example, amplification of the erbB2 gene is observed in 25 to 30% of breast cancer patients, and overexpression of the product correlates with an earlier relapse and poor prognosis (46, 47).”
BackgroundHurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y., Buyse, M., Mackey, J., Driga, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2294 · Cited by 115
“4 INTRODUCTION: Amplification of the HER2 gene is a key driver in the pathogenesis and biological aggressiveness of approximately 25% of breast cancer.(1) Trastuzumab, a humanized anti-HER2 monoclonal IgG1 antibody is known to significantly improve clinical outcome for both early and advanced HER2-positive breast canc…”
Discafani, C. M., Carroll, M. L., Floyd, M. B., Hollander, I. J., Husain, Z., Johnson, B. D., Kitchen, D., May, M. K., Malo, M. S., Minnick, A. A., et al. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00356-6 · Cited by 112
Regina, A., Demeule, M., Tripathy, S., Lord-Dufour, S., Currie, J.-C., Iddir, M., Annabi, B., Castaigne, J.-P., & Lachowicz, J. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0399 · Cited by 112
Mai, Z., Blackburn, G. L., & Zhou, J. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20300 · Cited by 111
Overexpression of the c-erbB-2 protein in human breast tumor cell lines
Hynes, N. E., Gerber, H. A., Saurer, S., & Groner, B. (1989) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240390208 · Cited by 109
Khan, M. W., Saadalla, A., Ewida, A. H., Al-Katranji, K., Al-Saoudi, G., Giaccone, Z. T., Gounari, F., Zhang, M., Frank, D. A., & Khazaie, K. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2057-0 · Cited by 103
“HER2/neu overexpression occurs in 20–30% of breast cancer cases and is associated with inflammatory tumors and poor prognosis [13].”
Studying copy number variations using a nanofluidic platform
Qin, J., Jones, R. C., & Ramakrishnan, R. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn518 · Cited by 102
“Although the clinical data (other than pathological classification) of these samples were lacking, about 35% of the samples had an increased number of this gene above 5, very close to the ERBB2 amplification frequency reported in the literature (67).”
ResultSingh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3628 · Cited by 99
Bartelink, I. H., Jones, E. F., Shahidi‐Latham, S. K., Lee, P. R. E., Zheng, Y., Vicini, P., van ‘t Veer, L., Wolf, D., Iagaru, A., Kroetz, D. L., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1211 · Cited by 96
Sirkisoon, S. R., Carpenter, R. L., Rimkus, T., Anderson, A., Harrison, A., Lange, A. M., Jin, G., Watabe, K., & Lo, H.-W. (2018) · Oncogene · doi:10.1038/s41388-018-0132-4 · Cited by 96
Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351354 · Cited by 95
Jäger, M., Schoberth, A., Ruf, P., Hess, J., & Lindhofer, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2861 · Cited by 94
“It is correlated with a poor prognosis, reducing progression-free outcomes and overall survival (4, 5).”
Background(2021) · doi:10.1038/s43018-021-00190-z · Cited by 92
Targeting the insulin growth factor receptor 1
Arnaldez, F. I., & Helman, L. J. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.01.004 · Cited by 88
“About 40% to 80% of NSCLCs have EGFR overexpression,(89) and 30% of breast cancers overexpress human epidermal growth factor receptor 2 (HER-2).(90,91) EGFR”
BackgroundRepp, R., van Ojik, H. H., Valerius, T., Groenewegen, G., Wieland, G., Oetzel, C., Stockmeyer, B., Becker, W., Eisenhut, M., Steininger, H., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601367 · Cited by 88
“This includes approximately 30% of breast cancer, in which it has been correlated with the development of metastases and is associated with poor prognosis (Slamon et al, 1987).”
BackgroundTargeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
Detection of HER2 amplification in circulating free DNA in patients with breast cancer
Page, K., Hava, N., Ward, B., Brown, J., Guttery, D. S., Ruangpratheep, C., Blighe, K., Sharma, A., Walker, R. A., Coombes, R. C., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.89 · Cited by 86
“The protein is overexpressed because of gene amplification in 20– 25% of breast cancers (Slamon et al, 1987), where it is a diagnostic marker for aggressive disease and increased risk of metastasis and thus poor prognosis (Ross and Fletcher, 1998).”
Raab, S. S., & Grzybicki, D. M. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20068 · Cited by 77
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
“Antigen Vaccine Name Vaccine Type Indication Clinical Trial # Clinical Outcome Ref # MUC1 Tecemotide/ L-BLP25 Peptide Stage III non-small-cell lung cancer, completed chemoradiotherapy NCT00409188 (Phase III) Median OS: 25.6 months to 22.3 months (treatment to control) [14] STn-KLH Glycopeptide Metastatic Breast Cancer…”
BackgroundInfluentialRepression of p63 and induction of EMT by mutant Ras in mammary epithelial cells
Yoh, K. E., Regunath, K., Guzman, A., Lee, S.-M., Pfister, N. T., Akanni, O., Kaufman, L. J., Prives, C., & Prywes, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613417113 · Cited by 75
“The EGFR2 receptor, also known as HER2/ neu, is an important upstream activator of Ras and is amplified in about 20–30% of breast cancers (4, 5).”
BackgroundSORLA regulates endosomal trafficking and oncogenic fitness of HER2
Pietilä, M., Sahgal, P., Peuhu, E., Jäntti, N. Z., Paatero, I., Närvä, E., Al-Akhrass, H., Lilja, J., Georgiadou, M., Andersen, O. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10275-0 · Cited by 75
Tanizaki, J., Okamoto, I., Fumita, S., Okamoto, W., Nishio, K., & Nakagawa, K. (2011) · Oncogene · doi:10.1038/onc.2011.111 · Cited by 70
HER3 Is an Actionable Target in Advanced Prostate Cancer
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3360 · Cited by 68
“Targeting ERBB signaling in clinical trials has to date failed to impart patient bene fi t, perhaps due to feedback loops, continued AR signaling, or insuf fi cient blockade of the entire ERBB axis (9, 10).”
BackgroundWray, N. R., & Maier, R. (2014) · Current Epidemiology Reports · doi:10.1007/s40471-014-0023-3 · Cited by 67
“, ER+ve/ER –ve and overexpression of HER2 as a breastcancer subtype [41, 42] or K-ras mutations in colorectal cancer and EGFR mutations in lung cancer, as reviewed in [43].”
BackgroundEffective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells
Mortenson, E. D., Park, S., Jiang, Z., Wang, S., & Fu, Y.-X. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2522 · Cited by 66
“and is associated with aggressive disease, a high recurrence rate, and reduced patient survival (3, 4).”
BackgroundKönigshoff, M., Wilhelm, J., Bohle, R. M., Pingoud, A., & Hahn, M. (2003) · Clinical Chemistry · doi:10.1373/49.2.219 · Cited by 63
“... tyrosine kinase activity and structural homology to the human epidermal growth factor receptor (EGFR; ERBB1) (1 ). HER-2/neu is expressed in many cell systems, triggers a rich network of signaling pathways, and plays an important role in normal growth and development (1, 2) . Oncogenic amplification of the HER-2/n…”
BackgroundRydén, L., Loman, N., Larsson, C., Hegardt, C., Vallon-Christersson, J., Malmberg, M., Lindman, H., Ehinger, A., Saal, L. H., & Borg, Å. (2018) · British Journal of Surgery · doi:10.1002/bjs.10741 · Cited by 62
Bowe, D. B., Kenney, N. J., Adereth, Y., & Maroulakou, I. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205025 · Cited by 61
“…homologue of Neu (c-erbB-2 or HER2), a member of the epidermal growth factor receptor family, is ampli®ed and/or overexpressed in 20 ± 45% of human mammary cancers and is associated with poor prognosis (Andrulis et al., 1998; Briscoe et al., 1993; Press et al., 1993; Slamon et al., 1987, 1989).”
BackgroundKourtidis, A., Srinivasaiah, R., Carkner, R. D., Brosnan, M. J., & Conklin, D. S. (2009) · Breast Cancer Research · doi:10.1186/bcr2240 · Cited by 60
“ERBB2 overexpression is a significant predictor of both overall survival and time to relapse [1].”
Pullarkat, V., Deo, Y., Link, J., Spears, L., Marty, V., Curnow, R., Groshen, S., Gee, C., & Weber, J. S. (1999) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050543 · Cited by 55
Lyon, E., Millson, A., Lowery, M. C., Woods, R., & Wittwer, C. T. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.5.844 · Cited by 54
Millson, A., Suli, A., Hartung, L., Kunitake, S., Bennett, A., Nordberg, M. C. L., Hanna, W., Wittwer, C. T., Seth, A., & Lyon, E. (2003) · The Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60471-0 · Cited by 51
Herceptin: From the Bench to the Clinic
Colomer, R., Shamon, L. A., Tsai, M. S., & Lupu, R. (2001) · Cancer Investigation · doi:10.1081/cnv-100000074 · Cited by 43
“The erbB-2 oncogene product has been shown to be expressed in approximately 25–30% of breast cancer patients and has been correlated with poor prognosis and unfavorable survival rate (3,4).”
BackgroundSestini, R., Orlando, C., Zentilin, L., Lami, D., Gelmini, S., Pinzani, P., Giacca, M., & Pazzagli, M. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.6.826 · Cited by 44
ScFv‐Decorated PEG‐PLA‐Based Nanoparticles for Enhanced siRNA Delivery to Her2+ Breast Cancer
Dou, S., Yang, X., Xiong, M., Sun, C., Yao, Y., Zhu, Y., & Wang, J. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400037 · Cited by 39
Plasmonic nanoplatforms: From surface‐enhanced Raman scattering sensing to biomedical applications
Cupil‐Garcia, V., Strobbia, P., Crawford, B. M., Wang, H., Ngo, H., Liu, Y., & Vo‐Dinh, T. (2021) · Journal of Raman Spectroscopy · doi:10.1002/jrs.6056 · Cited by 34
Sclafani, F., Roy, A., Cunningham, D., Wotherspoon, A., Peckitt, C., Gonzalez de Castro, D., Tabernero, J., Glimelius, B., Cervantes, A., Eltahir, Z., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt408 · Cited by 33
Elevation of SIPL1 (SHARPIN) increases breast cancer risk
De Melo, J., & Tang, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127546 · Cited by 33
YAP transcriptionally regulates ErbB2 to promote liver cell proliferation
Wang, E. Y., Cheng, J.-C., Thakur, A., Yi, Y., Tsai, S.-H., & Hoodless, P. A. (2018) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2018.07.004 · Cited by 24
HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients
Khalifa, S. E., & Fathy, Y. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.318 · Cited by 20
Facts and controversies in the use of trastuzumab in the adjuvant setting
Dinh, P., de Azambuja, E., Cardoso, F., & Piccart-Gebhart, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1219 · Cited by 19
“dtd" [ ]> Introduction Up to 25% of women with early-stage breast cancer have tumors that are positive for expression of the human epidermal growth factor receptor-2 (HER2), and these tumors are associated with an aggressive phenotype, a high recurrence rate and reduced survival”
BackgroundSchleidgen, S., & Marckmann, G. (2013) · BMC Medical Ethics · doi:10.1186/1472-6939-14-20 · Cited by 15
“The drug, especially when applied in combination with chemotherapy or as an adjuvant (postoperative) treatment, significantly improves the response rate and the progression-free as well as overall survival rate in patients with an overexpression of the HER2/neu receptor (HER2/neu positive) as compared to HER2/neu nega…”
Result
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.